Supinthara Sawatdee

Professional and experienced healthcare practitioner with solid background in clinical research and patient care. Skilled in data collection, patient monitoring, and protocol adherence. Strong focus on team collaboration and achieving results, adaptable to changing needs. Known for reliability, excellent communication, and analytical skills.

• Basic life support training , Bumrungrad Hospital
• Advanced cardiovascular life support (ACLS) training. Bumrungrad Hospital
• Nutritional management for the elderly,Thai Society of Gerontology and Geriatric Medicine
• FibroScan Operator Best Practices/Scan Review (Use Fibroscan 430)
• Conflicts of Interest for IRB members, Researchers, Faculty members
• GCP (ICH Focus) for IRB members, Researchers, Faculty members
• GCP (U.S. FDA Focus) for IRB members, Researchers, Faculty members
• GCP Clinical Trials Involving Investigational Devices for IRB members, Researchers, Faculty members
• IRB members, Researchers, Faculty members
• RCR for IRB members, Researchers, Faculty members
• Medidata Classic Rave EDC Essentials for Clinical Research Coordinator
• Medidata Classic Rave EDC Essentials for Read-Only Users
• Medidata Cloud Administration Navigation Bar
• IMedidata Account Management
• BOXI to BO4 Upgrade Training
• Overview of the Differences Between Classic Rave and Rave EDC in EDC
• Viedoc system has been certified as study coordinator
• InForm 6.x/7.xData Entry & Signatures Rev 1.00 (MRL-EXT-020331 Ver 1.3)
• Basic Site User Training (Offered by Florence Healthcare)
• Site Admin Training (Offered by Florence Healthcare)
• EBinders Training for Site Staff (Offered by Florence Healthcare)

• Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University
• Room 725 , Paettayaphat Building ,1873 Rama IV Road, Pathumwan, Bangkok, 10330 Thailand

Phase I Trial

• A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-506, an HBV Capsid Inhibitor, in Healthy Subjects and HBV-DNA Positive Subjects with Chronic HBV Infection
• A Three-Part, Phase 1, Safety. Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-HBVS in Healthy Volunteers and Patients with Chronic Hepatitis B
• A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
• BRII-179 (VBI-2601)-001, A Phase Ib/IIa Randomized, Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Antiviral Activity of BRII-179 (VBI-2601) among Subjects with Chronic Hepatitis B) Protocol Number: Brii-179-001
• A Single and Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Healthy Subjects and Subjects with Chronic Hepatitis B Infection
• A Phase 1/2Study to Evaluation the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination with Pegylated Interferon Alpha-2a
• A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-836, an HBV Capsid Inhibitor, in Healthy Subject and Subjects with Chronic HBV Infection
• A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic HBV Infection
• A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic HBV Infection and a Long-term Study to Evaluate the Safety, Tolerability, and Efficacy of BW-20507 in Subjects with Chronic HBV Infection

Phase II Trial

• A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
• A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
• Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients with Inactive Chronic Hepatitis B (CHB)
• A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection
• A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection” Protocol Number: Brii-835-002
• A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis
• A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Phase III Trial

• An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Phase IV Trial

• Efficacy and Liver Fibrosis Improvement in Patients with Chronic HCV Genotype 1 Infection with and without HIV Co-Infection Receiving the Combination Regimen of Grazoprevir/ Elbasvir therapy
• Comparison of the Effectiveness and Safety between Generic oral solution Entecavir (Encavir) and Original oral tablet Entecavir (Baraclude) in the treatment of Chronic hepatitis B infection in Chulalongkorn hospital
• Oligonol and its beneficial effects in non-alcoholic fatty liver disease (NAFLD)